Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) has announced its upcoming participation in the Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, November 19, 2024, at 12:00 p.m. GMT. Akero, which focuses on developing treatments for serious metabolic diseases, will make the presentation available via live webcast through their investor relations website. An archived replay will be accessible on www.akerotx.com following the live event.

News Market Reaction – AKRO

-3.91%

-3.91% Session move

In the trading session that priced this news, AKRO declined 3.91%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 12:00 p.m. GMT.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH (F2-F3) or compensated cirrhosis (F4) due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the completed HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the ongoing SYMMETRY study in patients with compensated cirrhosis (F4) due to MASH, in which more than 300 patients have been treated for up to 96 weeks. Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.

Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com

Media Contact:
Peg Rusconi
617.910.6217
peg.rusconi@deerfieldgroup.com

FAQ

When is Akero Therapeutics (AKRO) presenting at the Jefferies London Healthcare Conference 2024?

Akero Therapeutics will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 12:00 p.m. GMT.

How can I watch Akero Therapeutics' (AKRO) presentation at the Jefferies Conference?

The presentation can be viewed through a live webcast on Akero's investor relations website at www.akerotx.com, with an archived replay available afterward.

What type of presentation will Akero Therapeutics (AKRO) give at the Jefferies London Healthcare Conference?

Akero Therapeutics' management will participate in a fireside chat format presentation at the conference.

What is the focus area of Akero Therapeutics (AKRO)?

Akero Therapeutics is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases with high unmet medical need.